Biotech focus

Innovus (INNV) Licenses Urox® Formulation Targeting $3+ Billion Markets

Overactive bladder and urinary incontinence affects nearly 60 million Americans in a market that’s worth over $3 billion, according to the Simon Foundation and the National Association for Continence. Innovus Pharmaceuticals Inc. (OTCQB: INNV) aims to tap into the enormous market with a new exclusive licensing deal that it hopes will generate $3 million per year in revenue and bring it closer to bottom-line profitability.

In this article, we will take a closer look at the deal and where the company may be headed over the coming quarters.

Details of the Deal

Innovus Pharmaceuticals Inc. recently announced an exclusive licensing agreement with Seipel Group for the rights to market Urox® formulation to these large end markets. Under the agreement, the clinically proven herbal supplement will be marketed under the UriVarx™ brand name using Innovus’ Beyond Human Sales & Marketing Platform. The team aims to triple the product’s revenue from $1 million in 2015 to $3 million per year.

Urox® is a patented herbal supplement that has been clinically proven to reduce urgency and accidents for patients suffering from overactive bladder and urinary incontinence. In double-blind and comparative trials, researchers found a 56% reduction in urge incontinence, a 66% reduction in stress incontinence, a 61% reduction in urinary urgency, a 33% reduction in urinary frequency, and a 46% reduction in nocturia.

The transaction will make Urox® the 14th product launch for Innovus this year as it builds a robust pipeline of clinically proven over-the-counter supplements and over-the-counter drugs. By offering the product through its Beyond Human Platform reaching 20-30 million people on a monthly basis and to over 1.5 million subscribers, the company aims to generate immediate revenue that will help move it closer to profitability. The company will also leverage its significant reach into publications and retail locations to further drive long-term revenue. 

Growing Pipeline

Innovus Pharma has developed a portfolio of over-the-counter products targeting a wide array of different conditions. By leveraging its Beyond Human Platform, the company is able to effectively cross-sell these products to an audience of 20-30 million people on a monthly basis plus the 1.5 million subscribing customers as well as reach new customers through digital and in-person channels. The power of this platform has already been demonstrated by strong sales of its other products like Vesele®, RecalMax™ and Sensum+®.

In addition to this growing portfolio, the company’s FlutiCare™ product is pending ANDA approval from the FDA. If approved, the company will own an over-the-counter version of a leading prescription drug targeting the multi-billion-dollar allergy relief industry where millions of sufferers are in need of better solutions. The FDA decision is expected to be before the end of the year and could be a large potential catalyst for the stock.

The company differentiates itself from many other nutraceutical or botanical companies with its clinically proven products that have already achieved product-market fit. For example, Vesele® enhances blood flow and promotes sexual health, Zestra® boosts female arousal, EjectDelay® addresses premature ejaculation, and RecalMax™ improves cognitive function. All of these products have benefited from the robust Beyond Human marketing platform.

Looking Ahead

Innovus Pharmaceuticals, Inc. represents a compelling opportunity to invest in an early-stage pharmaceutical company that’s seeing strong revenue growth and is on track to become profitable over the near-term. With a market capitalization of approximately $25 million, the market may be undervaluing the stock based on its existing revenue, while discounting new product launches, revenue streams, and the potential for its FlutiCare™ ANDA coming down the road.

Investors may want to consider the micro-cap company for the speculative portion of their portfolios as a potentially high growth opportunity with numerous catalysts.

For more information, visit the company’s website at or learn more on at